1. Signaling Pathways
  2. Apoptosis
  3. TNF Receptor

TNF Receptor (肿瘤坏死因子)

Tumor Necrosis Factor Receptor; TNFR

肿瘤坏死因子 (TNF) 是细胞凋亡以及炎症和免疫的主要介质,并且与多种人类疾病的发病机制有关,包括败血症、糖尿病、癌症、骨质疏松症、多发性硬化症、类风湿性关节炎和炎症性肠病。

TNF-α 是一种 17 kDa 蛋白质,由 157 个氨基酸组成,在溶液中为同源三聚体。在人类中,该基因位于 6 号染色体上。其生物活性主要受可溶性 TNF-α 结合受体的调节。TNF-α 主要由活化的巨噬细胞、T 淋巴细胞和自然杀伤细胞产生。已知多种其他细胞的表达较低,包括成纤维细胞、平滑肌细胞和肿瘤细胞。在细胞中,TNF-α 合成为 pro-TNF (26 kDa),它与膜结合,在 TNF 转换酶 (TACE) 裂解其 pro 结构域后释放。

许多 TNF 诱导的细胞反应是由两种 TNF 受体 TNF-R1 和 TNF-R2 中的任一种介导的,这两种受体都属于 TNF 受体超家族。在 TNF 治疗后,转录因子 NF-κB 和 MAP 激酶(包括 ERK、p38 和 JNK)在大多数类型的细胞中被激活,在某些情况下,也可能诱导细胞凋亡或坏死。然而,诱导细胞凋亡或坏死主要是通过 TNFR1 实现的,TNFR1 也称为死亡受体。NF-κB 和 MAPK 的激活在多种细胞因子和免疫调节蛋白的诱导中起着重要作用,并且对许多炎症反应至关重要。

Tumor necrosis factor (TNF) is a major mediator of apoptosis as well as inflammation and immunity, and it has been implicated in the pathogenesis of a wide spectrum of human diseases, including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.

TNF-α is a 17-kDa protein consisting of 157 amino acids that is a homotrimer in solution. In humans, the gene is mapped to chromosome 6. Its bioactivity is mainly regulated by soluble TNF-α–binding receptors. TNF-α is mainly produced by activated macrophages, T lymphocytes, and natural killer cells. Lower expression is known for a variety of other cells, including fibroblasts, smooth muscle cells, and tumor cells. In cells, TNF-α is synthesized as pro-TNF (26 kDa), which is membrane-bound and is released upon cleavage of its pro domain by TNF-converting enzyme (TACE).

Many of the TNF-induced cellular responses are mediated by either one of the two TNF receptors, TNF-R1 and TNF-R2, both of which belong to the TNF receptor super-family. In response to TNF treatment, the transcription factor NF-κB and MAP kinases, including ERK, p38 and JNK, are activated in most types of cells and, in some cases, apoptosis or necrosis could also be induced. However, induction of apoptosis or necrosis is mainly achieved through TNFR1, which is also known as a death receptor. Activation of the NF-κB and MAPKs plays an important role in the induction of many cytokines and immune-regulatory proteins and is pivotal for many inflammatory responses.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-144368
    CO delivery molecule 1 Inhibitor
    CO delivery molecule 1 (compound 4) 定位于内质网、线粒体和溶酶体。CO delivery molecule 1 的亚细胞定位导致共诱导毒性效应。通过 TNF-α 抑制测定,CO delivery molecule 1 的抗炎作用在没有共释放的情况下发生在纳摩尔水平,并且随着可见光诱导的共释放而增强。
    CO delivery molecule 1
  • HY-146547
    Anti-inflammatory agent 17 Inhibitor
    Anti-inflammatory agent 17 是一种有效的具有口服活性的消炎药。Anti-inflammatory agent 17 在体外实验中抑制 IL-6 和 TNF-α 的释放且无细胞毒性。Anti-inflammatory agent 17 在体内显示出抗炎活性。Anti-inflammatory agent 17 具有研究急性肺损伤 (ALI) 的潜力。
    Anti-inflammatory agent 17
  • HY-P991510
    CDX-1140 Agonist
    CDX-1140 是一种人 IgG2 CD40 激动剂抗体。CDX-1140 可激活树突状细胞 (DC) 和 B 细胞,并在表达 CD40 的报告细胞系中驱动 NF-kB 刺激。CDX-1140 不依赖 FcR 结合,并与天然 CD40L 信号传导具有协同作用。CDX-1140 具有直接和免疫介导的抗肿瘤活性。 CDX-1140 可用于淋巴瘤和实体瘤的研究。
    CDX-1140
  • HY-111326S
    Naphazoline-d4 hydrochloride
    Naphazoline-d4 (hydrochloride) 是 Naphazoline hydrochloride 的氘代物。
    Naphazoline-d<sub>4</sub> hydrochloride
  • HY-N12042
    Taxamairin B Inhibitor
    Taxamairin B 是一种有效的抗炎剂。Taxamairin B 降低 LPS 诱导的 RAW264.7 细胞中促炎因子 (TNF-α, IL-1βIL-6) 的表达和 NOROS 的产生。Taxamairin B 对 LPS 诱导的急性肺损伤小鼠有明显的保护作用。
    Taxamairin B
  • HY-147950
    PDE4-IN-10 Inhibitor
    PDE4-IN-10 (compound 7a) 是一种有效的 PDE4 抑制剂,对 PDE4BIC50 值为 7.01 μM。PDE4-IN-10 表现出选择性,微粒体稳定性,对 TNF-α 有抑制作用,体外无明显毒性。
    PDE4-IN-10
  • HY-P990280
    Anti-Mouse CD27 Antibody (RM27-3E5) Inhibitor
    Anti-Mouse CD27 Antibody (RM27-3E5) 是大鼠来源的、抗小鼠 CD27IgG2a, κ 抗体抑制剂。
    Anti-Mouse CD27 Antibody (RM27-3E5)
  • HY-N8593S
    Undecane-d24
    Undecane-d24 是 Undecane 的氘代物。 Undecane 对致敏大鼠嗜碱性白血病(RBL-2H3)肥大细胞和 HaCaT 角质细胞有抗过敏和抗炎活性。在致敏肥大细胞中,抑制脱颗粒和组胺和 TNF-α 的分泌。
    Undecane-d<sub>24</sub>
  • HY-157809
    Anti-inflammatory agent 74 Inhibitor
    Anti-inflammatory agent 74 (B5) 是一种抗炎剂,能抑制 NOIL-6TNF-α,对 NOIL-6IC50 值为 10.88 μM 和 4.93 μM。Anti-inflammatory agent 74 通过调节炎症介质、抑制 MAPKNF-κB 信号通路来减轻急性肺损伤 (ALI)。
    Anti-inflammatory agent 74
  • HY-N0633R
    Muscone (Standard)

    麝香酮 (Standard)

    Inhibitor
    Muscone (Standard) 是 Muscone 的分析标准品。本产品用于研究及分析应用。Muscone 是中药麝香的主要活性单体。Muscone 抑制 NF-κBNLRP3 炎性小体的活化。Muscone 显着降低炎性细胞因子 (IL-1βTNF-αIL-6) 水平,并最终改善心脏功能和存活率。
    Muscone (Standard)
  • HY-160436
    TNF-α-IN-15 Inhibitor
    TNF-α-IN-15 是一种 TNF-α 抑制剂。 TNF-α-IN-15 可降低 TNF-α 血液水平。
    TNF-α-IN-15
  • HY-171468
    CC-1069 Inhibitor
    CC-1069,沙利度胺 (HY-14658) 的结构类似物,是一种 TNF-α 抑制剂,具有抑制内皮细胞增殖的作用。CC-1069 可以用于神经胶质瘤等血管生成依赖性肿瘤的研究。
    CC-1069
  • HY-159144
    Anti-inflammatory agent 91 Inhibitor
    Anti-inflammatory agent 91 (Compound 4o) 是一种抗炎剂,可以通过抑制 STAT3NF-κB 信号通路来减少炎性细胞因子。Anti-inflammatory agent 91 能用于改善银屑病的皮肤炎症的研究。
    Anti-inflammatory agent 91
  • HY-149496
    Akt/NF-κB/MAPK-IN-1 Inhibitor
    Akt/NF-κB/MAPK-IN-1 (compound 2m) 是一种口服有效的 NO 抑制剂 (IC50=7.70 μM),无明显毒性。Akt/NF-κB/MAPK-IN-1 通过抑制 Akt/NF-κB 和 MAPK 信号通路发挥抗炎活性。
    Akt/NF-κB/MAPK-IN-1
  • HY-P10797
    TAT-N24 Inhibitor
    TAT-N24 是一种细胞渗透性 TAT 肽,作为 p55PIK 信号抑制剂。TAT-N24 可通过抑制角膜缝合 (CS) 中 HIF-1α/NF-κB 信号通路,对角膜新生血管 (CNV) 和眼部炎症有效。TAT-N24 也抑制角膜新生血管形成。
    TAT-N24
  • HY-15643B
    LY 303511 dihydrochloride Activator
    LY 303511 dihydrochloride 是 LY294002 的一种结构类似物,但 LY 303511 dihydrochloride 不抑制 PI3K。LY 303511 dihydrochloride 可增强 SHEP-1 神经母细胞瘤细胞的TRAIL 敏感性。LY 303511 dihydrochloride 可逆地阻断 MIN6 胰岛瘤细胞中的 K+ 电流 (IC50=64.6±9.1 μM)。
    LY 303511 dihydrochloride
  • HY-N0261R
    Aurantio-obtusin (Standard)

    橙黄决明素 (Standard)

    Inhibitor
    Aurantio-obtusin (Standard) 是 Aurantio-obtusin 的分析标准品。本产品用于研究及分析应用。Aurantio-obtusin 是一种可以从决明子中提取的蒽醌类化合物。Aurantio-obtusin 具有降血压、降血脂和抗炎的作用。Aurantio-obtusin 是一种口服有效的血管扩张剂。Aurantio-obtusin 通过 AMPK/自噬和 AMPK/TFEB 介导的脂质积累抑制的途径来改善肝脂肪 变性 。
    Aurantio-obtusin (Standard)
  • HY-146419
    Anti-inflammatory agent 20 Inhibitor
    Anti-inflammatory agent 20 (化合物 5a) 是一种有效的 NO 活性抑制剂。Anti-inflammatory agent 20 具有抗炎活性。Anti-inflammatory agent 20 通过抑制 NF-κBMAPK 信号的激活从而降低 IL-6、TNF-α、iNOS 和 COX-2 的上调来抑制 LPS 诱导的炎症反应。
    Anti-inflammatory agent 20
  • HY-125740R
    Malvidin-3-glucoside chloride (Standard) Inhibitor
    Malvidin-3-glucoside (Malvidin-3-O-glucoside; Oenin) chloride (Standard) 是 Malvidin-3-glucoside chloride (HY-125740) 的分析标准品。本产品用于研究及分析应用。Malvidin-3-glucoside chloride 是口服有效的 NF-κB 通路抑制剂,可阻断 TNF-α 诱导的炎症反应,减少 IκB-α 降解及 p65 核转位,并上调内皮型一氧化氮合酶 eNOS 以增加 NO 生成。Malvidin-3-glucoside chloride 通过抑制 MCP-1ICAM-1IL-6 等促炎分子及调节肠道微生物和代谢物,发挥抗炎和抗氧化作用,同时保护内皮细胞并改善炎症状态下的肠道微生态失调。Malvidin-3-glucoside chloride 可用于研究动脉粥样硬化、炎症性肠病等慢性炎症相关疾病,具有预防血管炎症和改善肠道健康方面的潜力。
    Malvidin-3-glucoside chloride (Standard)
  • HY-P991393
    ASP8374 Activator
    ASP8374 是一种靶向 TIGIT 的人类 IgG4 单克隆抗体 (mAb)。ASP8374 可增加 Jurkat 细胞中 IL-2 的产生,并增加人 PBMC 中 IFN-γ 和 TNF-α 的产生。ASP8374 可用于晚期实体肿瘤的研究。推荐同型对照:Human IgG4 kappa,Isotype Control (HY-P99003)。
    ASP8374
目录号 产品名 / 同用名 种属 表达系统
目录号 产品名 / 同用名 应用 反应物种

Following the binding of TNF to TNF receptors, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I; TNFR2 binds to TRAF1/2 directly to recruit cIAP1/2. Both cIAP1 and cIAP2 are E3 ubiquitin ligases that add K63 linked polyubiquitin chains to RIPK1 and other components of the signaling complex. The ubiquitin ligase activity of the cIAPs is needed to recruit the LUBAC, which adds M1 linked linear polyubiquitin chains to RIPK1. K63 polyubiquitylated RIPK1 recruits TAB2, TAB3 and TAK1, which activate signaling mediated by JNK and p38, as well as the IκB kinase complex. The IKK complex then activates NF-κB signaling, which leads to the transcription of anti-apoptotic factors-such as FLIP and Bcl-XL-that promote cell survival. 

 

The formation of TNFR1 complex IIa and complex IIb depends on non-ubiquitylated RIPK1. For the formation of complex IIa, ubiquitylated RIPK1 in complex I is deubiquitylated by CYLD. This deubiquitylated RIPK1 dissociates from the membrane-bound complex and moves into the cytosol, where it interacts with TRADD, FADD, Pro-caspase 8 and FLIPL to form complex IIa. By contrast, complex IIb is formed when the RIPK1 in complex I is not ubiquitylated owing to conditions that have resulted in the depletion of cIAPs, which normally ubiquitylate RIPK1. This non-ubiquitylated RIPK1 dissociates from complex I, moves into the cytosol, and assembles with FADD, Pro-caspase 8, FLIPL and RIPK3 (but not TRADD) to form complex IIb. For either complex IIa or complex IIb to prevent necroptosis, both RIPK1 and RIPK3 must be inactivated by the cleavage activity of the Pro-caspase 8-FLIPL heterodimer or fully activated caspase 8. The Pro-caspase 8 homodimer generates active Caspase 8, which is released from complex IIa and complex IIb. This active Caspase 8 then carries out cleavage reactions to activate downstream executioner caspases and thus induce classical apoptosis. 

 

Formation of the complex IIc (necrosome) is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs, similar to complex IIa and complex IIb formation. RIPK1 recruits numerous RIPK3 molecules. They come together to form amyloid microfilaments called necrosomes. Activated RIPK3 phosphorylates and recruits MLKL, eventually leading to the formation of a supramolecular protein complex at the plasma membrane and necroptosis [1][2].

 

Reference:
[1]. Brenner D, et al. Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74. 
[2]. Conrad M, et al. Regulated necrosis: disease relevance and therapeutic opportunities.Nat Rev Drug Discov. 2016 May;15(5):348-66. 
 

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.